The clinical transition of GLP-1 therapeutics from specialized diabetes care to broad cardio-metabolic-renal risk reduction is expanding the addressable patient population exponentially. Detailed analysis within the GLP-1 Drug Market report reveals that clinical trial approvals for non-alcoholic steatohepatitis (NASH / MASH), chronic kidney disease (CKD), and obstructive sleep apnea are...